Health Condition 1: null- Women with histologically proven diagnosis of squamous cell carcinoma cervix FIGO stage IIB to IIIB will be included in the study.
Conditions
Interventions
Intervention1: Chemotherapy with low dose radiation therapy: Neoadjuvant chemotherapy with ultrafractionated radiotherapy
Inj Paclitaxel 175mg/m2, on day 1 of each cycle
Inj Carboplatin AUC Ã? 5, on d
Sponsors
Fluid Research Grant CMC Vellore
Eligibility
Inclusion criteria
Inclusion criteria: a. Inclusion Criteria: Women with histologically proven diagnosis of squamous cell carcinoma cervix FIGO stage IIB to IIIB will be included in the study. Inclusion criteria 1. Age less than or equal to 70 years 2. ECOG less than or equal to 2 3. Pretreatment Hb more than 9 gm% 4. Leucocytes more than or equal to 4000 / mm3 5. Platelets more than or equal to 1,00,000/mm3 6. Normal hepatic and renal parameters
Exclusion criteria
Exclusion criteria: Patients with renal, hepatic or cardiac co-morbidities or previous history of chemotherapy/radiation therapy/malignancy will be excluded
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| To assess efficacy of Neoadjuvant chemotherapy in combination with low dose radiotherapy in locally advanced Squamous cell carcinoma of cervix in terms of local control and overall survival at 1 yearTimepoint: 1 year | — |
Primary
| Measure | Time frame |
|---|---|
| Assess safety of using neoadjuvant chemotherapy with low dose radiation in locally advanced Squamous cell carcinoma of cervixTimepoint: during the phase of treatment | — |
Countries
India
Contacts
Public ContactSaikat Das
Christian Medical College Vellore
Outcome results
None listed